[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Seong SJ, Park H, Yang KM, Kim TJ, Lim KT, Shim JU, Park CT, Lee KH: Detection of sentinel lymph nodes in patients with early stage cervical cancer. J Korean Med Sci; 2007 Feb;22(1):105-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of sentinel lymph nodes in patients with early stage cervical cancer.
  • The purpose of this study was to determine the feasibility of identifying the sentinel lymph nodes (SNs) as well as to evaluate factors that might influence the SN detection rate in patients with cervical cancer of the uterus.
  • Eighty nine patients underwent intracervical injection of 1% isosulfan blue dye at the time of planned radical hysterectomy and lymphadenectomy between January 2003 and December 2003.
  • With the visual detection of lymph nodes that stained blue, SNs were identified and removed separately.
  • Then all patients underwent complete pelvic lymph node dissection and/or para-aortic lymph node dissection.
  • The most common site for SN detection was the external iliac area.
  • Metastatic nodes were detected in 21 of 89 (23.5%) patients.
  • Successful SN detection was more likely in patients younger than 50 yr (p=0.02) and with a history of preoperative conization (p=0.05).
  • However, stage, histological type, surgical procedure and neoadjuvant chemotherapy showed no significant difference for SN detection rate.
  • The SN detection rate was high in patients younger than 50 yr or with a history of preoperative conization.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gynaecol Oncol. 1995;16(4):274-7 [7556283.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] South Med J. 1999 Feb;92(2):204-8 [10071668.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1547-54 [10193945.001]
  • [Cites] Eur J Nucl Med. 1999 Apr;26(4 Suppl):S20-5 [10199929.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):281-8 [15961145.001]
  • [Cites] Cancer. 2000 May 15;88(10):2267-74 [10820348.001]
  • [Cites] Ann Surg Oncol. 2000 Jun;7(5):361-6 [10864344.001]
  • [Cites] Obstet Gynecol. 2000 Jul;96(1):135-8 [10928903.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):238-43 [11063651.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):411-5 [11104611.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):254-7 [11161868.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):688-93 [11821449.001]
  • [Cites] Breast J. 2002 Mar-Apr;8(2):88-91 [11896753.001]
  • [Cites] Anesth Analg. 2002 Aug;95(2):385-8, table of contents [12145056.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):507-11 [12172047.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):290-6 [12893189.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Dec;48(3):305-10 [14693343.001]
  • [Cites] Nucl Med Rev Cent East Eur. 2003;6(2):131-3 [14737728.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1919-20; author reply 1920 [15386330.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):941-6 [9753708.001]
  • (PMID = 17297260.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693543
  •  go-up   go-down


2. Tuomela JM, Valta MP, Väänänen K, Härkönen PL: Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer; 2008;8:81
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.
  • After sacrifice, the sizes of tumor-bearing prostates were measured and the tumors and prostate-draining regional iliac and sacral lymph nodes were excised for studies on markers of proliferation, apoptosis, angiogenesis and lymphangiogenesis, using histomorphometry and immunohistochemistry.
  • In the iliac and sacral lymph nodes of alendronate-treated mice, the proportion of metastatic area was only about 10% of that in control mice (p < 0.001).
  • Immunohistochemical staining of tumor sections showed that alendronate treatment caused a marked decrease in the number of CD34-positive endothelial cells in tumors (p < 0.001) and an increase in that of ISEL positive apoptotic cells in tumors as well as in lymph node metastases (p < 0.05) compared with those in the vehicle-treated mice.
  • CONCLUSION: Our results demonstrate that alendronate treatment opposes growth of orthotopic PC-3 tumors and decreases tumor metastasis to prostate-draining lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Alendronate / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphatic Metastasis / prevention & control. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Biomarkers, Tumor / analysis. Cell Division / drug effects. Humans. Male. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):10-7 [11134190.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4229-37 [11358849.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):1035-43 [11442499.001]
  • [Cites] Bone. 2001 Oct;29(4):336-43 [11595616.001]
  • [Cites] Breast Cancer Res. 2002;4(1):35-41 [11879558.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):946-51 [11948478.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2708-14 [11980672.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 [12359855.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6538-44 [12438248.001]
  • [Cites] J Urol. 2003 Jul;170(1):246-52 [12796698.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):225-54 [15163300.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):879-82 [15173273.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4559-67 [15240548.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Clin Exp Metastasis. 1998 May;16(4):332-9 [9626812.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):103-8 [9665470.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):887-94 [9714059.001]
  • [Cites] Clin Exp Metastasis. 1998 Nov;16(8):693-702 [10211982.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):1865-74 [15579431.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):540-5 [15695397.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):121-7 [15710325.001]
  • [Cites] J Urol. 2005 Mar;173(3):761-4 [15711264.001]
  • [Cites] BJU Int. 2005 May;95(7):935-8 [15839907.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2655-60 [16080508.001]
  • [Cites] Oncogene. 2005 Aug 18;24(35):5510-20 [15897888.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1713-20 [16121404.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36442-51 [16055444.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2522-9 [16270320.001]
  • [Cites] Treat Endocrinol. 2006;5(1):15-23 [16396515.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147(4):437-45 [16402039.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):7-26 [16601276.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2862-8 [16675582.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):739-49 [16954428.001]
  • [Cites] Oncologist. 2006 Nov-Dec;11(10):1121-31 [17110632.001]
  • [Cites] Eur J Pharmacol. 2007 Sep 10;570(1-3):27-37 [17640631.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s [17062708.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1480; author reply 1480-1 [15467039.001]
  • [Cites] Br J Radiol. 2004 Oct;77(922):869-70 [15483000.001]
  • [Cites] Cancer Res. 1975 Dec;35(12):3698-704 [1192428.001]
  • [Cites] Eur J Nucl Med. 1982;7(7):336-8 [6214400.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Prostate. 1989;15(2):187-94 [2529482.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 17;84(12):951-7 [1378502.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1751 [8612600.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Bone. 1996 Dec;19(6):663-7 [8968035.001]
  • [Cites] Invasion Metastasis. 1996;16(3):116-31 [9186547.001]
  • [Cites] J Bone Miner Res. 2003 Feb;18(2):204-12 [12568397.001]
  • [Cites] J Urol. 2003 Mar;169(3):849-54 [12576797.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2002;5(4):264-72 [12627210.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • (PMID = 18371232.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; X1J18R4W8P / Alendronate
  • [Other-IDs] NLM/ PMC2294135
  •  go-up   go-down


3. El Sayed S, Grando JP, Almeida SH, Mortati Neto N, Moreira HA: Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection. Int Braz J Urol; 2004 Sep-Oct;30(5):384-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
  • PURPOSE: To determine the role of RPLND for residual masses following chemotherapy in patients with non-seminomatous germ cell tumors (NSGCT) stage T1N2 and T1N3 (IIB and IIC).
  • MATERIALS AND METHODS: We have preformed retrospective analysis of 11 patients who underwent RPLND for residual masses following chemotherapy in an oncologic reference center between January 1997 and December 2002.
  • All patients harbored either pure nonseminomatous or mixed tumors in the testis tissue and had undergone 4 cycles of primary chemotherapy with bleomycin, etoposide and cisplatin.
  • The residual masses were assessed by abdominal computed tomography preoperatively.
  • One of who died in the early postoperative period due to extensive iliac thrombosis.
  • The other 2 patients had an inferior vena cava injury owing to the difficulty in removing the attached lymph nodes.
  • All patients had tumors in the final pathological report and were referred to other 2 cycles of chemotherapy with the same drugs.
  • The remaining 3 patients had disease progression, 2 of which died 6 and 12 months after surgery, respectively, and one patient missed the follow-up after salvage chemotherapy.
  • CONCLUSION: Retroperitoneal lymph node dissection for residual masses after chemotherapy is a high-morbidity procedure, even by experienced surgeons, although it remains an efficient modality of treatment in advanced germ cell carcinoma.
  • The high frequency of tumor found in the RPLFN following chemotherapy might have been caused by the small number of patients in this study.
  • [MeSH-major] Germinoma / drug therapy. Germinoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm, Residual. Retroperitoneal Space. Retrospective Studies

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610570.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Steven K, Poulsen AL: Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol; 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
  • PURPOSE: We assessed the clinical outcome in patients with invasive bladder cancer and lymph node metastasis above the bifurcation of the common iliac vessels treated with radical cystectomy including extended pelvic lymph node dissection without adjunct therapy.
  • MATERIALS AND METHODS: Between 1993 and June 2005 a total of 336 consecutive patients underwent radical cystectomy and extended pelvic lymphadenectomy without preoperative or postoperative chemotherapy by 1 surgeon.
  • The pelvic lymph node dissection began at the distal aorta including the common and external iliac lymph nodes, and the periaortic, presacral and obturator fossa nodes.
  • The lymphatic tissue removed above and below the bifurcation of the common iliac vessels was submitted separately for histopathological analysis.
  • Overall 64 patients (19%) had lymph node metastases of whom 22 (34.4%) had lymph node involvement above the bifurcation of the common iliac vessels outside the template of the standard lymph node dissection.
  • The median number of retrieved lymph nodes was 27 (range 7 to 78) and in those with lymph node metastases 27 (range 11 to 49) included 8 (range 0 to 17) above the bifurcation and 18 (range 8 to 41) below the bifurcation of the common iliac vessels in the true pelvis.
  • Lymph node involvement proved a significant adverse prognostic factor with a 5-year probability of survival of 39% vs 76%.
  • The overall 5-year survival rates was similar in patients with lymph node involvement above the bifurcation of the common iliac vessels (37%) compared to the entire population with lymph node metastasis (41%) and to those with lymphatic metastases in the true pelvis below the bifurcation of the common iliac vessels (42%).
  • The survival rate was significantly higher in patients with 5 or less involved lymph nodes (50% vs 13%, p <0.002) and in those with a lymph node density (number of lymph nodes involved/total number of lymph nodes removed) less than 20% (25% vs 47%, p <0.05), but it did not relate to the total number of retrieved lymph nodes.
  • CONCLUSIONS: Overall 34% of our patients with lymph node metastases had nodal involvement in the common iliac, periaortic and presacral regions after radical cystectomy for bladder cancer.
  • Survival was similar in this group of patients with lymphatic metastasis outside the boundaries of the standard pelvic lymph node dissection template compared to the entire population with lymph node metastasis.
  • Following radical cystectomy patients can be stratified into risk groups according to tumor stage, lymph node involvement, number of metastatic nodes and lymph node density.
  • Our results support the idea that the benchmark for radical cystectomy should include extensive pelvic lymph node dissection with anatomical boundaries including the common iliac and presacral nodes.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Iliac Artery / pathology. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Prospective Studies. Survival Analysis. Urinary Bladder / pathology. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698113.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Mossa B, Mossa S, Marziani R: Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer. Eur J Gynaecol Oncol; 2010;31(5):545-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer.
  • OBJECTIVE: The aim of this study was to evaluate whether the addition of adjuvant chemotherapy will improve the outcomes of high-risk patients with Stage IB, IIA squamous cervical carcinoma with positive pelvic and/or aortic nodes.
  • MATERIALS AND METHODS: 127 patients with Stage IB and IIA cervical carcinoma treated with radical hysterectomy and systematic pelvic/aortic lymphadenectomy (RS) and who had lymph node involvement, confirmed at the final histological examination were enrolled from January 1987 to December 2001.
  • All the patients received three cycles of adjuvant chemotherapy (AC) with cisplatin, bleomycin and vinblastine.
  • The results were compared with those obtained from a group of 136 patients with comparable age, stage and lymph node involvement, on whom radical surgery, systematic pelvic/aortic lymphadenectomy (RS) and adjuvant radiotherapy (RT) was performed on period 1971-1984.
  • The best results were however obtained with the common iliac and over two lymph node metastases.
  • CONCLUSIONS: Adjuvant chemotherapy in high-risk patients for lymph node positivity did not produce statistically significant results in terms of overall and disease-free survival vs adjuvant radiotherapy; however, a group of these patients, approximately 10%, could receive benefit from the treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant


6. Lefevre JH, Rondelli F, Mourra N, Bennis M, Tiret E, Parc R, Parc Y: Lumboaortic and iliac lymphadenectomy for lymph node recurrence of colorectal cancer: prognostic value of the MSI phenotype. Ann Surg Oncol; 2008 Sep;15(9):2433-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumboaortic and iliac lymphadenectomy for lymph node recurrence of colorectal cancer: prognostic value of the MSI phenotype.
  • BACKGROUND: Some patients have isolated lumboaortic and/or iliac lymph node recurrences (ILNR) of colorectal cancer.
  • Current guidelines recommend the use of chemotherapy.
  • METHODS: Medical notes, pathological findings, and surgical procedure of patients who underwent lymphadenectomy for ILNR of colorectal cancer between 1998 and 2005 were reviewed.
  • Two patients developed a postoperative complication.
  • Mean number of lymph nodes removed was 5.7 +/- 3.3.
  • CONCLUSION: Lymphadenectomy for ILNR of colorectal cancer is a feasible therapeutic option for selected patients.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / surgery. Microsatellite Instability. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adult. DNA Methylation. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Neoplasm Staging. Nuclear Proteins / genetics. Postoperative Complications. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18566862.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


7. Dhar NB, Campbell SC, Zippe CD, Derweesh IH, Reuther AM, Fergany A, Klein EA: Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int; 2006 Dec;98(6):1172-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection.
  • OBJECTIVES: To evaluate the rates of local and systemic progression (LP and SP), recurrence-free survival and overall survival for patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection (PLND) in 1987-2000.
  • All patients were staged N0M0 before RC, and none received neoadjuvant radiotherapy or chemotherapy.
  • The boundaries of the limited PLND were the pelvic side-wall between the genitofemoral and obturator nerves, and bifurcation of iliac vessels to the circumflex iliac vein.
  • LP was defined as a radiographic soft-tissue density of > or = 2 cm below the bifurcation of the aorta.
  • Pathological characteristics, based on the 1997 Tumour-Nodes-Metastasis system, recurrence patterns, and recurrence-free and overall survival, were determined.
  • RESULTS The median (range) overall follow-up was 45.1 (1.1-165.6) months; the number of lymph nodes (LNs) reported per patient was 12 (2-32).
  • [MeSH-major] Carcinoma / pathology. Lymph Node Excision / methods. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Survival Analysis. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956353.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Mossa B, Framarino ML, Napolitano C, Marziani R, Imperato F, Marzetti L: Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis? A long-term follow-up. Eur J Gynaecol Oncol; 2003;24(1):33-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis? A long-term follow-up.
  • OBJECTIVE: to verify the efficacy of adjuvant therapy in the prevention of neoplastic recurrence in patients at high risk for lymph-node involvement on surgical examination.
  • METHODS: 72 patients, suffering from squamous cell cervical carcinoma Stage IB-IIB (FIGO) who underwent radical hysterectomy with lymph-node involvement confirmed at the final histological examination, were enrolled.
  • All the patients were treated with adjuvant chemotherapy (AC), which included cisplatin, bleomycin and vinblastine, and were followed for a minimum period of six years.
  • The results were compared with those obtained with a historical group of 78 patients, with comparable age, stage and lymph-node involvement, on whom only radical surgery (RS) was performed.
  • The best results were obtained in cases where the common iliac lymph-nodes were affected, with the highest survival rate of 16.9% in the RS+AC group, out of a total of 25 cases.
  • CONCLUSIONS: adoption of adjuvant chemotherapy in patients at high risk for lymph-node positivity did not produce statistically significant results in terms of overall and disease-free survival; however, a small number of these patients, approximately 9%, could receive benefit from the treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Neoplasm Recurrence, Local / mortality. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Probability. Prognosis. Prospective Studies. Reference Values. Statistics, Nonparametric. Survival Analysis. Treatment Outcome


9. Querleu D, Dargent D, Ansquer Y, Leblanc E, Narducci F: Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas. Cancer; 2000 Apr 15;88(8):1883-91
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas.
  • METHODS: Fifty-three patients underwent infrarenal aortic and common iliac dissection for the staging of bulky or advanced cervical carcinomas.
  • The indication for extended lymph node staging was bulky early stage in 33 patients, International Federation of Gynecology and Obstetrics distal Stage IIB or higher in 14 patients, nonbulky early stage with microscopic positive pelvic lymph nodes in 1 patient, and central recurrence in 5 patients.
  • The lymph node dissection template included the common iliac lymph nodes, the inframesenteric lymph nodes, and the preaortic and lateroaortic infrarenal lymph nodes.
  • RESULTS: The procedure failed in two patients.
  • Nine patients had lymph node biopsy or selective removal of macroscopically positive lymph nodes.
  • For the 42 remaining patients, the average duration of the operation was 125.9 +/- 31.8 minutes and the average number of lymph nodes was 20.7.
  • Overall, 17 patients had positive lymph nodes, in whom disease was macroscopic in 9 patients and microscopic in 8.
  • All patients but one had external radiation therapy tailored according to the aortic lymph node status.
  • After an average follow-up of 18.9 months, 60% of lymph node positive patients and 15% of lymph node negative patients died.
  • Distant recurrence occurred in 53% of lymph node positive patients and 9% of lymph node negative patients.
  • No patient had recurrence in the aortic or common iliac area.
  • Two patients developed radiation enteritis.
  • CONCLUSIONS: This new technique deserves to be used as a tool to identify lymph node positive patients who require extended-field radiation and/or chemotherapy.
  • [MeSH-major] Lymph Node Excision / methods. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aorta. Endoscopy / methods. Female. Humans. Iliac Artery. Lymphatic Metastasis / diagnosis. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Treatment Outcome


10. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G: Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol; 2004 Oct;172(4 Pt 1):1286-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping.
  • PURPOSE: Accumulating evidence supports the relationship between an increased number of lymph nodes (LNs) reported following radical cystectomy (RC) and overall outcome.
  • MATERIALS AND METHODS: We conducted a prospective evaluation in which 144 patients undergoing RC and pelvic lymph node dissection (PLND) between June 2001 and April 2003 were included.
  • Lymph nodes were processed as individual packets.
  • A mixed statistical model was used with neoadjuvant chemotherapy, node status, pathological stage, bacillus Calmette-Guerin exposure, age and number of days from transurethral resection as the fixed effects.
  • RESULTS: The extended PLND group had a significantly greater lymph node yield (median 22.5 nodes) compared to standard PLND (median 8), however, no staging advantage was observed in the extended dissection group.
  • Only the type of PLND performed was associated with node yield (p <0.001).
  • Subset analysis of patients with unexpected microscopic nodal involvement revealed that 33% had involvement of the common iliac nodes.
  • CONCLUSIONS: In our series only the extent of the lymph node dissection was found to influence node yield significantly after radical cystectomy.
  • Additionally, the observed risk of involvement of the common iliac chain in microscopically node positive cases suggests a need to include this region as part of the PLND for bladder cancer for cases without grossly involved LNs.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / statistics & numerical data. Lymph Node Excision / statistics & numerical data. Lymph Nodes / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Models, Statistical. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15371825.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


11. Blanchard P, Plantade A, Pagès C, Afchain P, Louvet C, Tournigand C, de Gramont A: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol; 2007 Jan;104(1):41-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
  • Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy.
  • After initial optimal treatment, median progression-free survival (PFS) was 26 months.
  • Sites of relapse were retroperitoneum (n=15), left supraclavicular (n=7), mediastinum (n=4), iliac (n=4) and inguinal (n=3).
  • Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination.
  • Median OS from initial diagnosis was 68 months.
  • Time to relapse may not have its usual prognostic value.
  • Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952391.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kilçiksiz S, Gökçe T, Kinay M: Isolated inguinal lymph node metastasis from breast carcinoma--case report and review of the literature. J BUON; 2006 Apr-Jun;11(2):229-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated inguinal lymph node metastasis from breast carcinoma--case report and review of the literature.
  • We report on a case of a premenopausal woman with breast cancer and unusual dissemination with isolated inguinal and iliac lymph node metastasis.
  • Painful edema developed at the right leg 69 months after the operation.
  • Diagnostic investigations revealed isolated right inguinal and iliac lymphadenopathy (LAP).
  • Four months later, abdominal magnetic resonance imaging (MRI) disclosed paraaortic and bilateral iliac and inguinal LAP.
  • After unsuccesful chemotherapy, palliative RT was performed to the inguinal, iliac and paraaortic lymph nodes, resulting in partial response.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Female. Groin. Humans. Lymphatic Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318976.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Holmer M, Bendahl PO, Davidsson T, Gudjonsson S, Månsson W, Liedberg F: Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? World J Urol; 2009 Aug;27(4):521-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference?
  • OBJECTIVE: We compared extended and limited lymph node dissections performed during radical cystectomy with regard to impact on survival and time to recurrence in bladder cancer patients.
  • From 1997 to 2000, 69 of the patients were subjected to limited lymph dissection that included perivesical nodes and nodes in the obturator fossa.
  • In 2001-2005, the remaining 101 patients underwent extended lymph dissection that included perivesical nodes; nodes in the obturator fossa; the internal, external, and common iliac nodes; and the presacral nodes.
  • The median numbers of lymph nodes removed in the two groups were 37 and 8, respectively.
  • Lymph node metastases were detected in 38% of the extended dissection patients but only in 17% of the limited dissection patients.
  • There was no significant difference in survival or time to recurrence between the two groups.
  • Subgroup analyses showed a significantly longer time to recurrence (HR 0.45, 95% CI 0.22-0.93; P = 0.032) in patients with non-organ-confined disease who underwent extended lymph node dissection.
  • In a multivariate analysis adjusting for tumor stage, lymph node status, age, sex, and adjuvant chemotherapy, there was a significantly improved survival (HR 0.47, 95% CI 0.25-0.88; P = 0.018) and time to recurrence (HR 0.42, 95% CI 0.23-0.79; P = 0.007) in the patients with extended lymph node dissections.
  • CONCLUSIONS: Extended lymph node dissection did not improve disease-specific survival, but was in multivariate analysis related to significantly improved disease-specific survival and prolonged time to recurrence in radical cystectomy patients.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / surgery. Cystectomy. Lymph Node Excision / methods. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis / prevention & control. Neoplasm Recurrence, Local / prevention & control. Prognosis. Retrospective Studies. Treatment Outcome. Urothelium

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4 [17698113.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] BJU Int. 2007 Dec;100(6):1221-4 [17979920.001]
  • [Cites] J Urol. 1982 Jul;128(1):34-6 [7109065.001]
  • [Cites] Urology. 2003 Jan;61(1):105-8 [12559278.001]
  • [Cites] J Urol. 2003 Mar;169(3):946-50 [12576819.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1384-93; discussion 1393-4 [17764019.001]
  • [Cites] J Urol. 2004 May;171(5):1830-4 [15076287.001]
  • [Cites] J Urol. 2008 Mar;179(3):873-8; discussion 878 [18221953.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] BJU Int. 2000 May;85(7):817-23 [10792159.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):2015-9; discussion 2020 [9817313.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1286-90 [15371825.001]
  • [Cites] J Urol. 2006 Jan;175(1):84-8; discussion 88-9 [16406877.001]
  • (PMID = 19145436.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P: Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol; 2000 Mar;37(3):251-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer.
  • A laparoscopic dissection was used to assess the pathologic status of the relevant retroperitoneal lymph nodes.
  • MATERIAL AND METHODS: 17 patients were treated by a transperitoneal laparoscopic approach, whereas in the last 17 patients retroperitoneoscopic retroperitoneal lymph node dissection was performed.
  • The lymph node dissection was performed identically to open surgery with the modified template according to Weissbach including the paracaval, interaortocaval, upper pre-aortic, and right common iliac zonal nodes for right-sided tumors, and para-aortic, upper pre-aortic zones for left-sided tumors.
  • Retrieval of the lymph node chains was accomplished using a small organ bag.
  • RESULTS: The procedure could be completed successfully in 30 of 34 patients with stage-I disease.
  • In these cases the mean duration of the procedure was 248 min.
  • One patient developed a delayed ureteral stenosis which required operative repair.
  • One patient with a LRLA on the right side later developed retrograde ejaculation.
  • After a median follow-up of 40 months no regional relapse occurred, but 2 patients developed pulmonary metastases which were treated successfully by three cycles of platinum-based chemotherapy.
  • [MeSH-major] Germinoma / surgery. Laparoscopy. Lymph Node Excision / methods. Testicular Neoplasms / surgery
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Neoplasm Staging. Postoperative Complications / epidemiology. Retroperitoneal Space. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10720848.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


15. Querleu D, Ferron G, Rafii A, Bouissou E, Delannes M, Mery E, Gladieff L: Pelvic lymph node dissection via a lateral extraperitoneal approach: description of a technique. Gynecol Oncol; 2008 Apr;109(1):81-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic lymph node dissection via a lateral extraperitoneal approach: description of a technique.
  • OBJECTIVE: Locally advanced cervical cancers are generally managed by radiation and chemotherapy.
  • Pretherapeutic laparoscopic assessment of aortic nodes in patients with locally advanced cervical cancer offers valuable information for individualized treatment planning with minimal morbidity when the extraperitoneal approach is used.
  • Although the pioneers of the technique proposed to sample only the aortic and common iliac nodes, there is growing evidence that concomitant radiation and chemotherapy does not control all the diseased pelvic nodes.
  • As a result, diseased but not fixed pelvic nodes amenable to an attempt at laparoscopic removal should be debulked during the staging surgery.
  • METHODS: The left extraperitoneal approach routinely used for aortic and common iliac dissection has been extended to the pelvic area in eight patients.
  • RESULTS: The left pelvic dissection, including the removal of obturator nodes, has been successfully completed in all cases, including two patients with macroscopically diseased nodes.
  • CONCLUSION: The lateral extraperitoneal route used for the routine staging in our institution can be extended to the pelvic area without additional transumbilical transperitoneal laparoscopy, thus reducing the adhesion formation in patients candidates for definitive radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / methods. Lymph Nodes / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Pelvis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258287.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Fortunato L, Baldi A, Farina M, Campioni M, Amini M, Piro FR, Costarelli L, Pompili P, Vitelli CE: Bone marrow and sentinel lymph node biopsy in patients with breast cancer: from staging to ultrastaging? J Exp Clin Cancer Res; 2006 Dec;25(4):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow and sentinel lymph node biopsy in patients with breast cancer: from staging to ultrastaging?
  • Patients underwent SLN biopsy, and lymph nodes were analysed with serial sections and stained with hematossilin-eosin and immunohistochemistry.
  • At the end of the procedure a BM aspirate from the iliac crest was obtained and 5-10 cc of blood collected.
  • At a median follow up of 35 months 5/122 in the BM- group and 6/61 in the BM+ group have relapsed (p = 0.2), while 1/122 and 4/61 have died of disease (p = 0.04) In conclusion, ultrastaging of breast cancer patients may identify a substantial subgroup of patients N-/BM- who may not require adjuvant chemotherapy, as well as a subgroup N-/BM+ with a decreased survival who may need more aggressive therapies.
  • [MeSH-major] Bone Marrow / pathology. Breast Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310838.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / DNA Primers
  • [Number-of-references] 54
  •  go-up   go-down


17. Lerner SP: The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma. Curr Treat Options Oncol; 2009 Aug;10(3-4):267-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymph node metastases are the most important prognostic variable in determining outcome following radical cystectomy.
  • An anatomic bilateral node dissection includes at a minimum the external and internal iliac and obturator lymph nodes.
  • An extended node dissection may include the distal aortic and vena caval nodes, bilateral common iliac, and pre-sacral nodes, which receive direct lymphatic drainage from the posterior bladder and trigone.
  • This approach sets up the cystectomy, maximizes sensitivity for detection of nodal metastasis, assures optimum local pelvic cancer control, and accurately identifies those high-risk patients with node metastases who may benefit from adjuvant chemotherapy.
  • Lymph node retrieval is affected by several variables of node specimens addition to the anatomic extent of the node dissection.
  • These include presentation to the pathologist in packets, specimen processing and what the pathologist calls a lymph node, and patient age.
  • The current TNM staging system accounts for the number and size of node metastases and may be improved by incorporating lymph node density, which is a composite variable incorporating the number of positive nodes and number of nodes retrieved--a possible surrogate for the extent of the node dissection.
  • Innovations in imaging including novel MRI contrast agents and lymphoscintigraphy may improve the pre-treatment and intra-operative identification of node metastases and lymphatic anatomy.
  • Minimally invasive surgical techniques including robotic-assisted laparoscopic cystectomy may improve peri-operative outcomes but must meet the standard of anatomic node dissection and long-term cancer control afforded by the gold standard of anatomic radical cystectomy and bilateral pelvic and iliac node dissection.
  • [MeSH-major] Lymph Nodes / surgery. Lymphatic Metastasis. Pelvis / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Contrast Media / pharmacology. Humans. Magnetic Resonance Imaging. Medical Oncology / methods. Medical Oncology / trends. Neoplasm Staging. Prognosis. Radionuclide Imaging / methods. Robotics. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2009 Mar;16(3):274-8; discussion 278 [19087211.001]
  • [Cites] J Urol. 2008 Jan;179(1):34-45 [17997425.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4 [17698113.001]
  • [Cites] J Urol. 2003 Mar;169(3):943-5 [12576818.001]
  • [Cites] J Urol. 2003 Jul;170(1):35-41 [12796639.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201 [15939530.001]
  • [Cites] J Urol. 1982 Jul;128(1):34-6 [7109065.001]
  • [Cites] J Urol. 2001 Dec;166(6):2295-6 [11696756.001]
  • [Cites] J Urol. 2009 Jun;181(6):2490-5 [19371902.001]
  • [Cites] Urology. 2008 Jul;72(1):128-32 [18455773.001]
  • [Cites] Urol J. 2008 Spring;5(2):94-8 [18592461.001]
  • [Cites] Radiology. 2004 Nov;233(2):449-56 [15375228.001]
  • [Cites] J Urol. 2003 Mar;169(3):946-50 [12576819.001]
  • [Cites] J Urol. 2001 Jul;166(1):19-23 [11435814.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2368-74 [17041887.001]
  • [Cites] Eur Urol. 2008 Sep;54(3):690-1 [18792446.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Feb;19(1):71-4 [19288592.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Urol. 2004 May;171(5):1830-4 [15076287.001]
  • [Cites] BJU Int. 2009 May;103(10):1359-62 [19076140.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):369-75 [17762633.001]
  • [Cites] J Urol. 1993 Apr;149(4):758-64; discussion 764-5 [8455238.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] BJU Int. 2000 May;85(7):817-23 [10792159.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2253-7 [14634391.001]
  • [Cites] World J Urol. 2009 Feb;27(1):27-32 [19020882.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):806-12 [18085612.001]
  • [Cites] J Urol. 2004 Jan;171(1):139-44 [14665862.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):121-6 [18165646.001]
  • [Cites] J Urol. 2007 Mar;177(3):876-81; discussion 881-2 [17296365.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1809-12 [15540725.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1818-21 [15540728.001]
  • [Cites] Eur Urol. 2007 Dec;52(6):1708-9 [17646045.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):2015-9; discussion 2020 [9817313.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1286-90 [15371825.001]
  • [Cites] J Urol. 2006 Jan;175(1):84-8; discussion 88-9 [16406877.001]
  • (PMID = 19565335.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  • [Number-of-references] 39
  •  go-up   go-down


18. Angerer-Shpilenya M, Jakse G: [The significance of lymphadenectomy in the management of penile cancer]. Urologe A; 2009 Jan;48(1):54-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cases involving more than two positive lymph nodes or extranodal growth as well as positive imaging, pelvic lymphadenectomy is indicated.
  • Large or fixed inguinal nodes as well as iliac lymph nodes seen on computed tomography scanning are a good indication for neoadjuvant rather than adjuvant chemotherapy.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Lymph Node Excision / methods. Penile Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2008 Aug;102(3):305-9 [18410439.001]
  • [Cites] Curr Opin Urol. 2003 Nov;13(6):467-72 [14560140.001]
  • [Cites] J Urol. 1996 Nov;156(5):1637-42 [8863559.001]
  • [Cites] J Urol. 2005 Jan;173(1):198-201 [15592074.001]
  • [Cites] Eur Urol. 2005 May;47(5):601-6; discussion 606 [15826750.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] Urology. 2008 Feb;71(2):328-33 [18308113.001]
  • [Cites] Surg Gynecol Obstet. 1948 Dec;87(6):679-94 [18120502.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] J Urol. 2007 Mar;177(3):953-7; discussion 958 [17296386.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] J Urol. 2002 Jul;168(1):76-80 [12050496.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] World J Urol. 2006 Aug;24(3):319-24 [16688459.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] J Urol. 2002 Jan;167(1):89-92; discussion 92-3 [11743282.001]
  • [Cites] BJU Int. 2008 Nov;102(9):1102-6 [18489528.001]
  • [Cites] Urologe A. 2005 Jun;44(6):657-61 [15891865.001]
  • [Cites] J Urol. 1992 Mar;147(3):630-2 [1538445.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1638-9 [12356050.001]
  • [Cites] Int J Urol. 2005 Aug;12(8):776-8 [16174057.001]
  • [Cites] J Urol. 2005 Sep;174(3):923-7; discussion 927 [16093989.001]
  • [Cites] Urologe A. 2003 Nov;42(11):1466-9 [14624345.001]
  • [Cites] J Urol. 2000 Jan;163(1):100-4 [10604324.001]
  • [Cites] Eur Urol. 2004 Jun;45(6):761-5; discussion 765-6 [15149749.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):17-9; discussion 20-1 [17376585.001]
  • [Cites] J Urol. 2007 Mar;177(3):947-52; discussion 952 [17296384.001]
  • [Cites] Urology. 2007 Nov;70(5):975-9 [18068457.001]
  • [Cites] J Urol. 2001 May;165(5):1506-9 [11342906.001]
  • [Cites] BJU Int. 2007 Sep;100(3):561-5 [17578518.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):974-9 [18460979.001]
  • [Cites] BJU Int. 2003 Aug;92(3):248-50 [12887477.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] J Urol. 1994 May;151(5):1244-9 [7512656.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):488-94 [17316964.001]
  • [Cites] BJU Int. 2007 Jul;100(1):204-8 [17433031.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Urology. 2001 Jul;58(1):65-8 [11445481.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):170-7 [17316967.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Eur Urol. 2009 Mar;55(3):546-51 [18649992.001]
  • [Cites] Onkologie. 2008 Feb;31(1-2):37-41 [18268397.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2507-16 [15856474.001]
  • (PMID = 19099283.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 51
  •  go-up   go-down


19. Kanaev SV, Girshovich MM, Golovanov SG, Gershanovich ML: [Can extended induction chemoradiotherapy be effective in the combined treatment of stage IIIB Hodgkin's disease ?]. Vopr Onkol; 2009;55(5):562-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can extended induction chemoradiotherapy be effective in the combined treatment of stage IIIB Hodgkin's disease ?].
  • The paper evaluates the results of chemoradiaton (2-4 cycles of preliminary treatment to suppress intoxication symptoms plus total, or subtotal exposure of the lymph nodes to tumor-killing doses in cases of intact iliac inguinal nodes) in 89 patients with Hodgkin's disease stage IIIB.
  • It is concluded that, with our regimen, combined treatment will not be effective unless 75% or more regression of tumor is assured.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Remission Induction / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020650.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


20. Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, Kresnik E, Unterweger O, Linkesch W, Lind P: Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Acta Med Austriaca; 2003;30(2):41-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this retrospective study was to evaluate the accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) images, which were interpreted under daily routine conditions, in patients with Hodgkin's disease (HD) or non-Hodgkin lymphoma (NHL) for restaging after chemotherapy and/or radiotherapy.
  • METHODS: 121 PET images of 93 lymphoma patients (44 HD, 49 NHL) were investigated after chemotherapy/radiotherapy.
  • The morphological imaging consisted in computed tomography and ultrasound (CT/US) in all patients, additional MRI in some patients, and iliac crest biopsy in cases of suspicious bone marrow involvement.
  • The standard of reference was composed of biopsy data, clinical status at the time of investigation, and follow-up of at least 12 months.
  • Major sources of error in 18F-FDG-PET were due to asymmetric muscular hypermetabolism and inflammatory lesions misinterpreted as persistent viable lymphoma tissue.
  • Pharmacological muscular relaxation in the course of 18F-FDG-PET imaging may be advisable, as nonspecific muscular hypermetabolism was one of the problems at the image readings and a source of incorrect 18F-FDG-PET interpretations.
  • [MeSH-minor] Adolescent. Adult. False Negative Reactions. False Positive Reactions. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Hodgkin Disease / radionuclide imaging. Hodgkin Disease / radiotherapy. Humans. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Tissue Distribution. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12752087.001).
  • [ISSN] 0303-8173
  • [Journal-full-title] Acta medica Austriaca
  • [ISO-abbreviation] Acta Med. Austriaca
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Leblanc E, Caty A, Dargent D, Querleu D, Mazeman E: [Laparoscopic lumbo-aortic lymphadenectomy in early-stage non-seminomatous germ cell tumors of the testis: Why? How?]. Prog Urol; 2000 Jun;10(3):379-87
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Laparoscopic lumbo-aortic lymphadenectomy is proposed in order to decrease the morbidity of pretreatment lymph node dissections for early stage NSGCT of the testis.
  • MATERIAL AND METHODS: From 1991 to 1999, 57 patients with clinical stage I (50) to IIA (7) NSGCT underwent pretreatment laparoscopic investigation of the para-aortic lymph nodes: 32 transumbilical transperitoneal dissections and 25 internal iliac extraperitoneal dissections were performed.
  • RESULTS: Only the 19 patients with lymph node invasion received chemotherapy.
  • CONCLUSIONS: Laparoscopy, especially extraperitoneal, appears to be a safe, effective and appropriate modality for pretreatment lumbo-aortic lymph node evaluation in early stage NSGCT of the testis.
  • [MeSH-major] Germinoma / surgery. Laparoscopy. Lymph Node Excision / methods. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10951930.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


22. Heidenreich A, Ohlmann C, Hegele A, Beyer J: Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol; 2005 Jan;47(1):64-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Repeat retroperitoneal lymph node dissection (RPLND) for the treatment of metastatic testicular cancer is an uncommonly performed procedure.
  • We evaluated the location, pathohistological results, postoperative complications and therapeutic outcome in 17 patients being referred for repeat RPLND after failure of the primary retroperitoneal approach.
  • RESULTS: All patients had nonseminomatous primaries with metastatic retroperitoneal lymph nodes; 4 and 14 patients had undergone primary RPLND and residual tumor resection (RTR), respectively, for metastatic testicular cancer.
  • Prior to repeat RPLND all patients had undergone 4 cycles of salvage chemotherapy for locoregional recurrences only with negative tumour markers at time of surgery.
  • Retroperitoneal recurrences were located at multiple sites: retrocaval area with infiltration of the vena cava, interaortocaval and paraaortic region, retrocrural space, suprahilar region, outfield metastases in the iliac region.
  • Two cases required resection of the vena cava due to infiltration, in one case an aortic graft and an iliac graft was necessary due to tumour infiltration of the adventitial layer of the vessels; nephrectomy and resection of the sigmoid was required in another 2 patients.
  • [MeSH-major] Germinoma / pathology. Germinoma / surgery. Lymph Node Excision. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Retroperitoneal Space. Retrospective Studies

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582251.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Paule B: [Does radiotherapy still have a place in the treatment of stage I seminoma?]. Prog Urol; 2004 Jun;14(3):281-6; discussion 285-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does radiotherapy still have a place in the treatment of stage I seminoma?].
  • [Transliterated title] La radiothérapie a-t-elle encore une place dans le traitement du séminome stade I?
  • For the last 60 years, radiotherapy delivering 30 Gy to homolateral iliac and paraaortic lymph nodes has been the standard treatment for clinical stage I seminoma.
  • The risk appears to be low with low-dose (20 Gy) irradiation techniques.
  • However, the late effects of radiotherapy have led to the search for alternative adjuvant approaches, including surveillance and carboplatin chemotherapy.
  • Finally, experience with surveillance strategies in patients with stage I seminoma have allowed a meta-analysis of predictive factors for relapse, distinguishing patients requiring post-orchidectomy adjuvant therapy from those who can be easily followed by a surveillance strategy.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Radiotherapy / adverse effects. Radiotherapy / methods

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15373167.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 52
  •  go-up   go-down


24. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann KU, Bamberg M: Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol; 2003 Mar 15;21(6):1101-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A prospective multicenter trial was initiated to evaluate the role of modern radiotherapy with reduced treatment portals for stage IIA and IIB testicular seminoma.
  • Staging comprised computed tomography of the chest, abdomen, and pelvis as well as analysis of tumor markers alpha-fetoprotein and beta human chorionic gonadotropin.
  • Linac-based radiotherapy was delivered to para-aortic and high ipsilateral iliac lymph nodes.
  • The total doses were 30 Gy for stage IIA and 36 Gy for stage IIB disease.
  • Median time to follow-up of 87 assessable patients was 70 months.
  • All patients were treated with a salvage regimen of platinum-based chemotherapy.
  • CONCLUSION: Radiotherapy for stages IIA/B seminoma with reduced portals yields excellent tumor control at a low rate of acute toxicity and no late toxicity, which supports the role of radiotherapy as the first treatment choice for these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Seminoma / pathology. Seminoma / radiotherapy. Testicular Neoplasms / pathology. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Confidence Intervals. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prospective Studies. Radiotherapy / adverse effects. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12637477.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds
  •  go-up   go-down


25. MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR: Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis; 2007;24(7):521-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TNFerade is a replication incompetent adenovector designed to express human TNFalpha under control of the Egr-1 radiation and chemotherapy enhanced promoter, and is currently in Phase II/III clinical testing.
  • Data from Phase I clinical testing of TNFerade in a limited set of melanoma patients suggested the potential to impact distal metastases following intratumoral injections of TNFerade.
  • These clinical observations and the multiple potential mechanisms of TNFerade led us to hypothesize local treatment with TNFerade + radiation may impact metastatic disease.
  • Established subcutaneous B16F10 tumors were treated with intratumoral injections of TNFerade and localized 2 Gy fractionated radiation therapy, modeling the clinical treatment regimen.
  • Following 10-14 days of treatment, mice were evaluated for metastases development in the iliac and axillary lymph nodes.
  • Comparisons of metastatic burden to control groups indicated TNFerade +/- radiation suppressed the formation of metastases in the lymph nodes.
  • Additional experiments in TNF receptor knockout mice, where the only possible effects are on tumor cells containing the TNFalpha receptor, indicate TNFerade's local and distal activities are critically dependent on a host-mediated response.
  • These data provide direct preclinical evidence local therapy of a solid tumor with TNFerade can also reduce metastatic disease, in addition to effects on the treated lesion.
  • Furthermore, our finding of a host dependant response(s) for TNFerade at both the treated tumor and on lymph node metastases suggest the potential for broad activity independent of tumor histology.
  • [MeSH-major] Gene Transfer Techniques. Genetic Therapy. Melanoma / therapy. Neoplasms / therapy. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adenoviridae / genetics. Adult. Animals. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Genetic Vectors. Humans. Lymphatic Metastasis / prevention & control. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Middle Aged. Neoplasm Transplantation. Receptors, Tumor Necrosis Factor / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43 [11698568.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6278-86 [11086063.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1167-75 [15367711.001]
  • [Cites] Hum Gene Ther. 2002 Jan 20;13(2):275-86 [11812283.001]
  • [Cites] J Invest Dermatol. 1998 Sep;111(3):497-502 [9740247.001]
  • [Cites] Radiology. 2001 Apr;219(1):166-70 [11274552.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4311-4 [8813113.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2830-4 [1849278.001]
  • [Cites] J Surg Oncol. 2004 Jul 1;86(4):172-8 [15221923.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6635-44 [15557154.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] Melanoma Res. 2001 Feb;11(1):21-30 [11254112.001]
  • [Cites] Cancer Gene Ther. 2001 Jul;8(7):497-505 [11498771.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):750-1 [16341000.001]
  • [Cites] Hum Gene Ther. 2001 Nov 20;12(17):2035-49 [11747595.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1957-66 [10940885.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10149-53 [1332031.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1258-70 [11948141.001]
  • [Cites] Exp Mol Pathol. 2001 Jun;70(3):317-25 [11418010.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):413-23 [12872364.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):348-51 [7566090.001]
  • [Cites] DNA Cell Biol. 2003 Dec;22(12):755-63 [14683586.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Control. 1995 Oct;2(5):398-404 [10862180.001]
  • [Cites] Ann Surg Oncol. 2005 Oct;12(10):825-30 [16132372.001]
  • [Cites] J Exp Med. 1998 Oct 19;188(8):1391-9 [9782116.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):592-601 [14726502.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):6812-20 [11739497.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):736-46 [12951580.001]
  • [Cites] Int J Mol Med. 1999 Jan;3(1):49-57 [9864385.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):512-6 [1090362.001]
  • [Cites] Hum Gene Ther. 1998 Oct 10;9(15):2231-41 [9794207.001]
  • [Cites] Nat Med. 1995 Aug;1(8):786-91 [7585181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2419-22 [8384722.001]
  • [Cites] Cancer Gene Ther. 1999 May-Jun;6(3):271-81 [10359213.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Aug;4(7):687-94 [16884670.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):403-10 [12163460.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5747-53 [15355902.001]
  • [Cites] Lymphology. 1983 Dec;16(4):243-6 [6664119.001]
  • [Cites] Cancer Metastasis Rev. 2006 Jun;25(2):257-67 [16770538.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] Gene Ther. 1999 Mar;6(3):338-49 [10435084.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3042-51 [12824250.001]
  • [Cites] Cancer Gene Ther. 2002 Nov;9(11):951-7 [12386834.001]
  • [Cites] J Immunol. 1996 Sep 1;157(5):1919-25 [8757310.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):20-3 [6833336.001]
  • [Cites] J Virol. 1996 Sep;70(9):6497-501 [8709289.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2001 Jun;47(4):619-35 [11502070.001]
  • [Cites] J Virol. 2002 Apr;76(8):3670-7 [11907206.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2353s-2358s [16609058.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):665-71 [12424068.001]
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1296-302 [11123429.001]
  • [Cites] Cell Mol Life Sci. 1998 Dec;54(12):1291-8 [9893706.001]
  • [Cites] Cancer Gene Ther. 2000 Dec;7(12):1543-56 [11228533.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4824-9 [7585514.001]
  • [Cites] Hum Gene Ther. 2005 Jan;16(1):91-100 [15703492.001]
  • [Cites] Cancer Gene Ther. 1999 Sep-Oct;6(5):409-22 [10505851.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2156-60 [1900938.001]
  • [Cites] J Anat. 1971 Sep;109(Pt 3):369-83 [5153800.001]
  • (PMID = 17653822.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111423; United States / NCI NIH HHS / CA / R43CA105733
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


26. Bauduceau O, Souleau B, Le-Moulec S, Houlgatte A, Bernard O: [Radiotherapy in stage I testicular seminoma: retrospective study and review of literature]. Cancer Radiother; 2003 Dec;7(6):386-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Radiothérapie des séminomes testiculaires de stade I : étude rétrospective et revue de la littérature.
  • Patients have been treated using an anterior-posterior parallel pair and have received 20-25 Gy in 10-14 fractions.
  • The target volume consisted of paraaortic, and paraaortic + homolateral iliac lymph nodes in 17 and 46 patients, respectively.
  • Median follow-up time was 37 months.
  • DISCUSSION: Because of good radio-sensitivity of seminoma, radiotherapy is regarded as standard adjuvant treatment (5 years relapse rate: 3-5%).
  • Secondary neoplasia represents one of the worst possible long-term complications of therapy.
  • Waiting for ongoing randomised trials, the modern literature for seminoma reflects a trend toward lower radiation doses (20-25 Gy) and smaller treatment volumes (paraaortic field).
  • Adjuvant chemotherapy with two courses of carboplatin, might be equivalent to radiotherapy but must be investigated in randomised trials.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Orchiectomy. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Testis / pathology. Time Factors

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14725912.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


27. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol; 2001 Feb 01;19(3):666-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
  • PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary bladder tumor stage and regional lymph node status with clinical outcomes.
  • PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 and December 1997, with or without adjuvant radiation or chemotherapy, were evaluated.
  • The 5- and 10-year recurrence-free survival for patients with organ-confined, lymph node-negative tumors was 92% and 86% for P0 disease, 91% and 89% for Pis, 79% and 74% for Pa, and 83% and 78% for P1 tumors, respectively.
  • Patients with muscle invasive (P2 and P3a), lymph node-negative tumors had 89% and 87% and 78% and 76% 5- and 10-year recurrence-free survival, respectively.
  • Patients with nonorgan-confined (P3b, P4), lymph node-negative tumors demonstrated a significantly higher probability of recurrence compared with those with organ-confined bladder cancers (P <.001).
  • A total of 246 patients (24%) had lymph node tumor involvement.
  • The 5- and 10-year recurrence-free survival for these patients was 35%, and 34%, respectively, which was significantly lower than for patients without lymph node involvement (P <.001).
  • Patients could also be stratified by the number of lymph nodes involved and by the extent of the primary bladder tumor (p stage).
  • Patients with fewer than five positive lymph nodes, and whose p stage was organ-confined had significantly improved survival rates.
  • The median time to recurrence among those patients in whom the cancer recurred was 12 months (range, 0.04 to 11.1 years).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157016.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kanaev SV, Gershanovich ML, Pozharisskiĭ KM, Girshovich MM, Malinin AP, Golovanov SG: [Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease]. Vopr Onkol; 2004;50(6):652-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with stage III (A,B) Hodgkin's disease (366) received chemoradiotherapy consisting of 2-4 courses of combined modality treatment followed by total or subtotal irradiation of lymph nodes.
  • Subtotal exposure proved relatively more effective in such patients without iliac and inguinal lymph node involvement.
  • If, following combined modality therapy, intoxication symptoms were aborted in stage IIIB patients; fairly good results were obtained after total and subtotal irradiation of lymph nodes or involved areas (10-year (70%) and 15-year (65%) overall and 10-year (75%) and 15-year (75%) relapse-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755057.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


29. Zarbo R, Scibilia G, Conoscenti G, Scollo P: Ovarian cystic teratoma with primary epithelial cell melanoma. Eur J Gynaecol Oncol; 2005;26(1):71-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare case of malignant melanoma arising in a cystic teratoma of the ovary occurring in a 60-year-old woman who died in four months despite the combined treatment administrated (surgery and chemotherapy).
  • Diagnosis of ovarian melanoma was confirmed by immunohistochemical positivity to S-100 protein and HMB 45.
  • There was no evidence of extra-ovarian primary melanoma on clinical examination; therefore the diagnosis was primary ovarian melanoma.
  • Melanoma metastases were detected on the uterus, the right ovary, the omentum and in one of the three excised left external iliac lymph nodes.
  • [MeSH-major] Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755005.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 41
  •  go-up   go-down


30. Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR: Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol; 2001 Dec;8(10):771-8
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival after a CR may be influenced by various factors, particularly out-of-field disease in iliac lymph nodes (ILN) identified during lower-extremity ILP.
  • METHODS: From May 1992 to July 1997, 50 patients (16 men and 34 women; median age, 57 years) with stage IIIA or IIIAB melanoma had a CR to a 90-minute hyperthermic iliac ILP with melphalan (10 mg/L limb volume, n = 20) or melphalan and tumor necrosis factor (4-6 mg+/-200 microg interferon; n = 30).
  • By univariate analysis, there was a trend for improved outcome with female sex and stage IIIA (vs. IIIAB) at initial diagnosis was associated with improved survival after a CR to ILP (P = .056 and .012, respectively).
  • The probability of overall in-field recurrence was 70% after 4 years, and there was no difference between those with or without positive ILNs; median time to in-field recurrence was 13 and 19 months, respectively (P = .62).
  • Of note, Cox models identified that the risk of death was significantly greater in those with a history of prior systemic therapy (hazard ratio: 2.67 [95% confidence interval, 1.17-6.11]; P = .02) and those with an in-transit lesion size > or =1.4 cm2 (hazard ratio, 3.12 [95% confidence interval, 1.30-7.5]; P = .011).
  • In addition, patients who have a CR after ILP and have a history of prior treatment or larger lesions should be considered for adjuvant systemic therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion / methods. Disease-Free Survival. Extremities / blood supply. Female. Humans. Hyperthermia, Induced / methods. Interferons / administration & dosage. Lymphatic Metastasis. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Staging. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776490.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 9008-11-1 / Interferons; Q41OR9510P / Melphalan
  •  go-up   go-down






Advertisement